Diphtheria, tetanus and pertussis vaccine - Tianjin CanSino Biotechnology
Alternative Names: Component pertussis based adult and adolescent vaccine; Tdcp adolescent and adult - Tianjin CanSino Biotechnology; Tdcp vaccineLatest Information Update: 09 Jan 2025
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Diphtheria; Pertussis; Tetanus
Most Recent Events
- 20 Dec 2024 Phase-II/III clinical trials in Diphtheria (In adolescents, In children, In the elderly, Prevention, In adults) in China (Unspecified route) (NCT06708286)
- 20 Dec 2024 Phase-II/III clinical trials in Pertussis (In adolescents, In children, In the elderly, Prevention, In adults) in China (Unspecified route) (NCT06708286)
- 20 Dec 2024 Phase-II/III clinical trials in Tetanus (In adolescents, In children, In the elderly, Prevention, In adults) in China (Unspecified route) (NCT06708286)